XML 63 R16.htm IDEA: XBRL DOCUMENT v2.4.0.8
OPERATING AND REPORTABLE SEGMENTS
 9 Months Ended
Sep. 30, 2014
Segment Reporting [Abstract]  
Operating and Reportable Segments
OPERATING AND REPORTABLE SEGMENTS

Following the sale of substantially all of the Company’s Home Health Services segment, the Company’s operating and reportable segments, “Infusion Services,” and “PBM Services,” reflect how the Company’s chief operating decision maker reviews the Company’s results in terms of allocating resources and assessing performance.

The Infusion Services operating and reportable segment provides services consisting of home infusion therapy, respiratory therapy and the provision of durable medical equipment, products and services. Infusion services include the dispensing and administering of infusion-based drugs, which typically require additional nursing and clinical management services, equipment to administer the correct dosage and patient training designed to improve patient outcomes. Home infusion services also include the dispensing of certain self-injectable therapies.

The PBM Services operating and reportable segment consists of integrated pharmacy benefit management (“PBM”) services, which primarily consists of discount card programs. The discount card programs provide a cost effective alternative for individuals who may be uninsured, underinsured or may have restrictive coverage that disallows reimbursement for certain medications. Under these discount programs, individuals who present a discount card at any of the Company’s participating network pharmacies receive prescription medications at a discounted price compared to the retail price.

The Company’s chief operating decision maker evaluates segment performance and allocates resources based on Segment Adjusted EBITDA. Segment Adjusted EBITDA is defined as income (loss) from continuing operations, net of income taxes adjusted for net interest expense, income tax expense (benefit), depreciation, amortization of intangibles and stock-based compensation expense and prior to the allocation of certain corporate expenses. Segment Adjusted EBITDA excludes acquisition, integration, and transitional expenses; restructuring expense; and other expenses related to the Company’s strategic assessment. Segment Adjusted EBITDA also excludes the operating losses of start-up branch locations that the Company has invested in organically rather than through acquisition. Segment Adjusted EBITDA is a measure of earnings that management monitors as an important indicator of operating and financial performance. The accounting policies of the operating and reportable segments are consistent with those described in the Company’s summary of significant accounting policies.

As a result of the sale of substantially all of the Company’s Home Health Services segment, prior period operating results and supplementary data have been reclassified to exclude the Home Health Services segment.



Segment Reporting Information
(in thousands)
 
Three Months Ended 
 September 30,
 
Nine Months Ended 
 September 30,
 
2014
 
2013
 
2014
 
2013
Results of Operations:
 
 
 
 
 
 
 
Revenue:
 
 
 
 
 
 
 
Infusion Services - product revenue
$
226,421

 
$
169,011

 
$
667,601

 
$
469,594

Infusion Services - service revenue
5,122

 
5,614

 
15,559

 
15,282

Total Infusion Services revenue
231,543

 
174,625

 
683,160

 
484,876

PBM Services - service revenue
12,416

 
16,006

 
47,217

 
59,098

Total revenue
$
243,959

 
$
190,631

 
$
730,377

 
$
543,974

 
 
 
 
 
 
 
 
Adjusted EBITDA by Segment before corporate overhead:
 
 
 

 
 
 
 

Infusion Services
$
(6,344
)
 
$
14,623

 
$
24,811

 
$
40,615

PBM Services
1,625

 
4,274

 
5,137

 
15,385

Total Segment Adjusted EBITDA
(4,719
)
 
18,897

 
29,948

 
56,000

 
 
 
 
 
 
 
 
Corporate overhead
(7,893
)
 
(7,483
)
 
(22,385
)
 
(23,531
)
 
 
 
 
 
 
 
 
Interest expense, net
(9,563
)
 
(7,183
)
 
(29,197
)
 
(20,169
)
Loss on extinguishment of debt
—

 
(15,898
)
 
—

 
(15,898
)
Income tax (expense) benefit
(1,930
)
 
13

 
(8,484
)
 
42

Depreciation
(4,205
)
 
(3,225
)
 
(11,999
)
 
(8,169
)
Amortization of intangibles
(1,620
)
 
(1,009
)
 
(4,943
)
 
(4,801
)
Stock-based compensation expense
(1,753
)
 
(1,427
)
 
(6,637
)
 
(7,260
)
Acquisition and integration expenses
(2,922
)
 
(4,890
)
 
(14,754
)
 
(13,025
)
Restructuring and other expenses and investments
(2,970
)
 
(1,551
)
 
(12,991
)
 
(4,604
)
Loss from continuing operations, net of income taxes
$
(37,575
)
 
$
(23,756
)
 
$
(81,442
)
 
$
(41,415
)
 
 
 
 
 
 
 
 
Supplemental Operating Data
 

 
 

 
 
 
 
 
 
September 30,
2014
 
December 31,
2013
Total Assets:
 
 
 
 
Infusion Services
 
$
783,658

 
$
793,475

PBM Services
 
29,009

 
25,239

Corporate unallocated, including cash and cash equivalents
 
46,169

 
53,169

Assets from discontinued operations
 
—

 
64,959

Assets associated with discontinued operations, not sold
 
7

 
16

Total Assets
 
$
858,843

 
$
936,858